· Regulation · Regulation Desk
HHS Secretary Robert F. Kennedy Jr. is pushing the FDA to reconsider roughly 12–14 peptides — including BPC-157, TB-500, and MOTS-c — removed from 503A compounding eligibility in 2020. A science-first read on which compounds are on the docket, what the evidence actually shows, and what an easing would mean for compounding pharmacies.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.